Citations (149)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Wenting Du & Rolf A. Brekken. (2018) Does Axl have potential as a therapeutic target in pancreatic cancer?. Expert Opinion on Therapeutic Targets 22:11, pages 955-966.
Read now
Read now
Alvarez Hector, Elizabeth A. Montgomery, Collins Karikari, Marcia I. Canto, Kerry B. Dunbar, Jean S. Wang, Georg Feldmann, Seung-Mo Hong, Michael C. Haffner, Alan K. Meeker, Sacha J. Holland, Jiaxin Yu, Thilo J. Heckrodt, Jing Zhang, Pingyu Ding, Dane Goff, Rajinder Singh, Juan Carlos Roa, Arivusudar Marimuthu, Gregory J. Riggins, James R. Eshleman, Barry D. Nelkin, Akhilesh Pandey & Anirban Maitra. (2010)
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
. Cancer Biology & Therapy 10:10, pages 1009-1018.
Read now
Read now
Rachel MA Linger, Amy K Keating, H Shelton Earp & Douglas K Graham. (2010) Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets 14:10, pages 1073-1090.
Read now
Read now
Articles from other publishers (146)
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp & Douglas K. Graham. (2023) TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nature Reviews Clinical Oncology 20:11, pages 755-779.
Crossref
Crossref
Nataliya Pidkovka & Abbes Belkhiri. (2023) Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target. Frontiers in Oncology 13.
Crossref
Crossref
Yonggang He, Wen Huang, Yichen Tang, Yuming Li, Xuehui Peng, Jing Li, Jing Wu, Nan You, Ling Li, Chuang Liu, Lu Zheng & Xiaobing Huang. (2023) Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. Frontiers in Oncology 13.
Crossref
Crossref
Xiaoqian Zhai, Dan Pu, Rulan Wang, Jiabi Zhang, Yiyun Lin, Yuqing Wang, Ni Zhai, Xuan Peng, Qinghua Zhou & Lu Li. (2023) Gas6/AXL pathway: immunological landscape and therapeutic potential. Frontiers in Oncology 13.
Crossref
Crossref
Yuanzhuo Gu, Zhengkui Zhang & Peter ten Dijke. (2023) Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cellular & Molecular Immunology 20:4, pages 318-340.
Crossref
Crossref
Ozden Oz, Asuman Argon, TuluAyata Kebat, Ozlem Ozdemir & Savas Yakan. (2023) Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas. Indian Journal of Pathology and Microbiology 66:3, pages 533.
Crossref
Crossref
Marie Mikuteit, Stefanie Zschäbitz, Christine Stöhr, Edwin Herrmann, Iris Polifka, Abbas Agaimy, Lutz Trojan, Philipp Ströbel, Frank Becker, Christian Wülfing, Peter Barth, Michael Stöckle, Michael Staehler, Christian Stief, Axel Haferkamp, Markus Hohenfellner, Stefan Duensing, Stephan Macher-Göppinger, Bernd Wullich, Joachim Noldus, Walburgis Brenner, Frederik Roos, Bernhard Walter, Wolfgang Otto, Maximilian Burger, Maximillian Erlmeier, Andres Jan Schrader, Arndt Hartmann, Franziska Erlmeier & Sandra Steffens. (2023) Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma. Urologia Internationalis 107:7, pages 713-722.
Crossref
Crossref
Yihao Liu, Minmin Shi, Xingfeng He, Yizhi Cao, Pengyi Liu, Fanlu Li, Siyi Zou, Chenlei Wen, Qian Zhan, Zhiwei Xu, Jiancheng Wang, Baofa Sun & Baiyong Shen. (2022) LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Shingpan Chan, Yunong Zhang, Jie Wang, Qiuchun Yu, Xia Peng, Jian Zou, Licheng Zhou, Li Tan, Yunxin Duan, Yang Zhou, Hoon Hur, Jing Ai, Zhen Wang, Xiaomei Ren, Zhang Zhang & Ke Ding. (2022) Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. Journal of Medicinal Chemistry 65:22, pages 15374-15390.
Crossref
Crossref
Gaia Bellomo, Carolyn Rainer, Valeria Quaranta, Yuliana Astuti, Meirion Raymant, Elzbieta Boyd, Ruth Stafferton, Fiona Campbell, Paula Ghaneh, Christopher M Halloran, Dean E Hammond, Jennifer P Morton, Daniel Palmer, Dale Vimalachandran, Robert Jones, Ainhoa Mielgo & Michael C Schmid. (2022) Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut 71:11, pages 2284-2299.
Crossref
Crossref
Lavanya Nagamalla, J. V. Shanmukha Kumar, Mohammed Rafi Shaik, Chintakindi Sanjay, Ali M. Alsamhan, Mohsin Ahmed Kasim & Abdulrahman Alwarthan. (2022) Identification of Novel AXL Kinase Inhibitors Using Ligand-Based Pharmacophore Screening and Molecular Dynamics Simulations. Crystals 12:8, pages 1158.
Crossref
Crossref
Riley D.Z. Mullins, Ananya Pal, Thomas F. Barrett, Molly E. Heft Neal & Sidharth V. Puram. (2022) Epithelial–Mesenchymal Plasticity in Tumor Immune Evasion. Cancer Research 82:13, pages 2329-2343.
Crossref
Crossref
Vinicius Ferreira da Paixão, Omar Julio Sosa, Diogo Vieira da Silva Pellegrina, Bianca Dazzani, Thalita Bueno Corrêa, Ester Risério Bertoldi, Luís Bruno da Cruz e Alves-de-Moraes, Diogo de Oliveira Pessoa, Victoria de Paiva Oliveira, Ricardo Alberto Chiong Zevallos, Lilian Cristina Russo, Fabio Luis Forti, João Eduardo Ferreira, Helano Carioca Freitas, José Jukemura, Marcel Cerqueira César Machado, Maria Dirlei Begnami, João Carlos Setubal, Daniela Sanchez Bassères & Eduardo Moraes Reis. (2022) Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma. Cellular Oncology 45:3, pages 479-504.
Crossref
Crossref
Agnete S. T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, Jean-Paul Thiery, James B. Lorens, Salem Chouaib & Stéphane Terry. (2022) Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Frontiers in Immunology 13.
Crossref
Crossref
Lavanya Nagamalla, J.V. Shanmukha Kumar, Chintakindi Sanjay, Ali M Alsamhan & Mohammed Rafi Shaik. (2022) In-silico study of seaweed secondary metabolites as AXL kinase inhibitors. Saudi Journal of Biological Sciences 29:2, pages 689-701.
Crossref
Crossref
MayadaS Farrag, Mohamed Elmetwally, NesrineS Farrag & AfafT Ibrahiem. (2022) Aldehyde dehydrogenase 1 expression in invasive breast carcinoma and its correlation with other clinicopathological parameters. Egyptian Journal of Pathology 42:2, pages 117.
Crossref
Crossref
Yuqing Zhang, Emily N. Arner, Ali Rizvi, Jason E. Toombs, Huocong Huang, Steven L. Warner, Jason M. Foulks & Rolf A. Brekken. (2022) AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer. Molecular Cancer Therapeutics 21:1, pages 38-47.
Crossref
Crossref
Se-Hee Kim, Sangtae Choi & Won-Suk Lee. (2021) Bevacizumab and anexelekto inhibitor, TP-0903 inhibits TGF-β1-induced epithelial–mesenchymal transition of colon cancer cells. Anti-Cancer Drugs 33:1, pages e453-e461.
Crossref
Crossref
Neus Martínez-Bosch, Helena Cristóbal, Mar Iglesias, Meritxell Gironella, Luis Barranco, Laura Visa, Domenico Calafato, Silvia Jiménez-Parrado, Julie Earl, Alfredo Carrato, Noemí Manero-Rupérez, Mireia Moreno, Albert Morales, Carmen Guerra, Pilar Navarro & Pablo García de Frutos. (2022) Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. eBioMedicine 75, pages 103797.
Crossref
Crossref
Maria L. Lotsberg, Kjersti T. Davidsen, Stacey D’Mello Peters, Gry S. Haaland, Austin Rayford, James B. Lorens & Agnete S. T. Engelsen. 2022. Biomarkers of the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment
307
327
.
Rolf A. Brekken & Katarzyna Wnuk-Lipinska. 2022. Biomarkers of the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment
183
194
.
Mai Tanaka & Dietmar W. Siemann. (2021) Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer. International Journal of Molecular Sciences 22:18, pages 9953.
Crossref
Crossref
Wenting Du, Natalie Z. Phinney, Huocong HuangZhaoning Wang, Jill WestcottJason E. ToombsYuqing ZhangMuhammad S. Beg, Thomas M. WilkieJames B. LorensRolf A. Brekken. (2021) AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. Molecular Cancer Research 19:8, pages 1412-1421.
Crossref
Crossref
Dandan Xu, Deqiao Sun, Wei Wang, Xia Peng, Zhengsheng Zhan, Yinchun Ji, Yanyan Shen, Meiyu Geng, Jing Ai & Wenhu Duan. (2021) Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry 220, pages 113497.
Crossref
Crossref
Chih‐Ming Su, Tung‐Wei Hsu, Shian‐Ying Sung, Ming‐Te Huang, Kuan‐Chou Chen, Chih‐Yang Huang, Chien Yi Chiang, Yen‐Hao Su, Hsin‐An Chen & Po‐Hsiang Liao. (2021)
AXL
is crucial for
E1A
‐enhanced therapeutic efficiency of
EGFR
tyrosine kinase inhibitors through
NFI
in breast cancer
. Environmental Toxicology 36:7, pages 1278-1287.
Crossref
Crossref
Mai Tanaka, Samantha S. Dykes & Dietmar W. Siemann. (2021) Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling. Clinical & Experimental Metastasis 38:3, pages 321-335.
Crossref
Crossref
Hefeng Zhang, Xia Peng, Yang Dai, Jingwei Shao, Yinchun Ji, Yiming Sun, Bo Liu, Xu Cheng, Jing Ai & Wenhu Duan. (2021) Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor. Journal of Medicinal Chemistry 64:7, pages 3956-3975.
Crossref
Crossref
Martha Wium, Aderonke F. Ajayi-Smith, Juliano D. Paccez & Luiz F. Zerbini. (2021) The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers 13:7, pages 1521.
Crossref
Crossref
Shengda Xie, Huiru Zhang, Zhenjie Liang, Xingmiao Yang & Ruibing Cao. (2021) AXL, an Important Host Factor for DENV and ZIKV Replication. Frontiers in Cellular and Infection Microbiology 11.
Crossref
Crossref
Sidney Iriana, Kumari Asha, Miroslava Repak & Neelam Sharma-Walia. (2021) Hedgehog Signaling: Implications in Cancers and Viral Infections. International Journal of Molecular Sciences 22:3, pages 1042.
Crossref
Crossref
Mitchell S. von Itzstein, Michael C. Burke, Rolf A. Brekken, Todd A. Aguilera, Herbert J. Zeh & Muhammad Shaalan Beg. (2020) Targeting TAM to Tame Pancreatic Cancer. Targeted Oncology 15:5, pages 579-588.
Crossref
Crossref
Yeon-Sang Ryu, Sangyun Shin, Hong-Gyu An, Tae-Uk Kwon, Hyoung-Seok Baek, Yeo-Jung Kwon & Young-Jin Chun. (2020) Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. Biomolecules & Therapeutics 28:5, pages 473-481.
Crossref
Crossref
Sima Ardalan Khales, Mohammad Reza Abbaszadegan, Ahmad Majd & Mohammad Mahdi Forghanifard. (2020) TWIST1 upregulates matrix metalloproteinase (MMP) genes family in esophageal squamous carcinoma cells. Gene Expression Patterns 37, pages 119127.
Crossref
Crossref
Cheong A. Bae, In-Hye Ham, Hye Jeong Oh, Dagyeong Lee, Jongsu Woo, Sang-Yong Son, Jung Hwan Yoon, James B. Lorens, Rolf A. Brekken, Tae-Min Kim, Sang-Uk Han, Won Sang Park & Hoon Hur. (2020) Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer 23:5, pages 824-836.
Crossref
Crossref
Karin Juliane Pelizzaro Rocha-Brito, Emanuella Maria Barreto Fonseca, Breno Germano de Freitas Oliveira, Ângelo de Fátima & Carmen Veríssima Ferreira-Halder. (2020) Calix[6]arene diminishes receptor tyrosine kinase lifespan in pancreatic cancer cells and inhibits their migration and invasion efficiency. Bioorganic Chemistry 100, pages 103881.
Crossref
Crossref
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, Takeshi Kitazaki, Akihiro Nishiyama, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Kohei Tanaka, Ryohei Kozaki, Seiji Yano & Koichi Takayama. (2020)
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
EGFR
-Mutated Non–Small Cell Lung Cancer
. Clinical Cancer Research 26:9, pages 2244-2256.
Crossref
Crossref
Lucy Ireland, Teifion Luckett, Michael C. Schmid & Ainhoa Mielgo. (2020) Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis. Frontiers in Immunology 11.
Crossref
Crossref
Edita Sarukhanyan, Sergey Shityakov & Thomas Dandekar. (2020) Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer. Frontiers in Chemistry 7.
Crossref
Crossref
Xianzhou Song, Hironari Akasaka, Hua Wang, Reza Abbasgholizadeh, Ji-Hyun Shin, Fenglin Zang, Jiayi Chen, Craig D. Logsdon, Anirban Maitra, Andrew J. Bean & Huamin Wang. (2020) Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. Journal of Biological Chemistry 295:8, pages 2348-2358.
Crossref
Crossref
Beatriz Guijarro, Isabella Bitetto, Gianfranco D’Onghia, Maria Cristina Follesa, Kostas Kapiris, Alessandro Mannini, Olivera Marković, Reno Micallef, Sergio Ragonese, Kostas Skarvelis & Angelo Cau. (2020) Spatial and temporal patterns in the Mediterranean populations of <em>Aristaeomorpha foliacea</em> and <em>Aristeus antennatus</em> (Crustacea: Decapoda: Aristeidae) based on the MEDITS surveys. Scientia Marina 83:S1, pages 57.
Crossref
Crossref
Taha Azad, Kazem Nouri, Helena J. Janse van Rensburg, Sarah M. Maritan, Liqing Wu, Yawei Hao, Tess Montminy, Jihang Yu, Prem Khanal, Lois M. Mulligan & Xiaolong Yang. (2019) A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis. Oncogene 39:2, pages 334-355.
Crossref
Crossref
Chien-Huang Liao, Chen-Yin Yong, Gi-Ming Lai, Jyh-Ming Chow, Chieh-Fang Cheng, Chia-Lang Fang, Pei-Chun Lin, Chia-Lun Chang, Yu-Mei Zheng, Shuang-En Chuang, Jacqueline Whang-Peng & Chih-Jung Yao. (2020)
Astragalus
Polysaccharide (PG2) Suppresses Macrophage Migration Inhibitory Factor and Aggressiveness of Lung Adenocarcinoma Cells
. The American Journal of Chinese Medicine 48:06, pages 1491-1509.
Crossref
Crossref
Congjun Xu, Yufei Han, Sicong Xu, Ruxin Wang, Ming Yue, Yu Tian, Xiaofan Li, Yanfang Zhao & Ping Gong. (2020) Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker. European Journal of Medicinal Chemistry 186, pages 111867.
Crossref
Crossref
Nellie K. McDaniel, Samantha R. Fischbach, Olivia J. Ondracek, Noah B. Welke, Mari Iida & Deric L. Wheeler. 2020. Improving the Therapeutic Ratio in Head and Neck Cancer. Improving the Therapeutic Ratio in Head and Neck Cancer
159
192
.
Chenjing Zhu, Yuquan Wei & Xiawei Wei. (2019) AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Molecular Cancer 18:1.
Crossref
Crossref
Emily N. Arner, Wenting Du & Rolf A. Brekken. (2019) Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. Frontiers in Oncology 9.
Crossref
Crossref
Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko, Satoshi Konagai, Hiroko Yamamoto, Takahiro Matsuya, Masatoshi Yuri, Yosuke Yamanaka, Masamichi Mori, Masahiro Takeuchi, Hiroyuki Koshio, Masaaki Hirano & Sadao Kuromitsu. (2019) Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression. Molecular Cancer Therapeutics 18:8, pages 1366-1373.
Crossref
Crossref
Yanting Duan, Longlong Luo, Chunxia Qiao, Xinying Li, Jing Wang, Hao Liu, Tingting Zhou, Beifen Shen, Ming Lv & Jiannan Feng. (2019) A novel human anti‐AXL monoclonal antibody attenuates tumour cell migration. Scandinavian Journal of Immunology 90:2.
Crossref
Crossref
Chia‐Chang Hsu, Pei‐Min Hsieh, Yaw‐Sen Chen, Gin‐Ho Lo, Hung‐Yu Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Yao‐Li Chen, Ming‐Lung Yu & Chih‐Wen Lin. (2019) Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection. Cancer Medicine 8:7, pages 3453-3463.
Crossref
Crossref
Pranathi Tata, Piyush Gondaliya, Aditya Sunkaria, Akshay Srivastava & Kiran Kalia. (2019) Modulation of CD44, EGFR and RAC Pathway Genes (WAVE Complex) in Epithelial Cancers. Current Pharmaceutical Design 25:8, pages 833-848.
Crossref
Crossref
Jane Antony, Jean Paul Thiery & Ruby Yun-Ju Huang. (2019) Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. Physical Biology 16:4, pages 041004.
Crossref
Crossref
Yanting Duan, Bo Hu, Chunxia Qiao, Longlong Luo, Xinying Li, Jing Wang, Hao Liu, Tingting Zhou, Beifen Shen, Ming Lv & Jiannan Feng. (2019) Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration. Oncology Letters.
Crossref
Crossref
Juliano D. Paccez, Kristal Duncan, Durairaj Sekar, Ricardo G. Correa, Yihong Wang, Xuesong Gu, Manoj Bashin, Kelly Chibale, Towia A. Libermann & Luiz F. Zerbini. (2019) Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. Oncogenesis 8:3.
Crossref
Crossref
Kei Namba, Kazuhiko Shien, Yuta Takahashi, Hidejiro Torigoe, Hiroki Sato, Takahiro Yoshioka, Tatsuaki Takeda, Eisuke Kurihara, Yusuke Ogoshi, Hiromasa Yamamoto, Junichi Soh, Shuta Tomida & Shinichi Toyooka. (2019)
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
EGFR
-Mutant Non–Small Cell Lung Cancer Cells
. Molecular Cancer Research 17:2, pages 499-507.
Crossref
Crossref
Manoj Kumar Kashyap & Omar Abdel-Rahman. (2018) Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Molecular Cancer 17:1.
Crossref
Crossref
Laëtitia GorisseZhigang LiAndrew C. HedmanDavid B. Sacks. (2018) IQGAP1 binds the Axl receptor kinase and inhibits its signaling. Biochemical Journal 475:19, pages 3073-3086.
Crossref
Crossref
Martha Wium, Juliano Paccez & Luiz Zerbini. (2018) The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview. Cells 7:10, pages 166.
Crossref
Crossref
Yingying Shen, Xiguang Chen, Jun He, Duanfang Liao & Xuyu Zu. (2018) Axl inhibitors as novel cancer therapeutic agents. Life Sciences 198, pages 99-111.
Crossref
Crossref
Kathleen F. Ludwig, Wenting Du, Noah B. Sorrelle, Katarzyna Wnuk-Lipinska, Mary Topalovski, Jason E. Toombs, Victoria H. Cruz, Shinichi Yabuuchi, N.V. Rajeshkumar, Anirban Maitra, James B. Lorens & Rolf A. Brekken. (2018) Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Cancer Research 78:1, pages 246-255.
Crossref
Crossref
Pinar Kanlikilicer, Bulent Ozpolat, Burcu Aslan, Recep Bayraktar, Nilgun Gurbuz, Cristian Rodriguez-Aguayo, Emine Bayraktar, Merve Denizli, Vianey Gonzalez-Villasana, Cristina Ivan, Ganesh L.R. Lokesh, Paola Amero, Silvia Catuogno, Monika Haemmerle, Sherry Yen-Yao Wu, Rahul Mitra, David G. Gorenstein, David E. Volk, Vittorio de Franciscis, Anil K. Sood & Gabriel Lopez-Berestein. (2017) Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy - Nucleic Acids 9, pages 251-262.
Crossref
Crossref
Guoan Zhang, Xia Kong, Meng Wang, Hongli Zhao, Sha Han, Ronghang Hu, Jian Huang & Wen Cui. (2017) AXL is a marker for epithelial‑mesenchymal transition in esophageal squamous cell carcinoma. Oncology Letters.
Crossref
Crossref
Jun Ho Yi, Jiryeon Jang, Jeonghee Cho, In-Gu Do, Mineui Hong, Seung Tae Kim, Kyoung-Mee Kim, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim & Jeeyun Lee. (2015) MerTK is a novel therapeutic target in gastric cancer. Oncotarget 8:57, pages 96656-96667.
Crossref
Crossref
Ketan S. Gajiwala, Neil Grodsky, Ben Bolaños, Junli Feng, RoseAnn Ferre, Sergei Timofeevski, Meirong Xu, Brion W. Murray, Ted W. Johnson & Al Stewart. (2017) The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. Journal of Biological Chemistry 292:38, pages 15705-15716.
Crossref
Crossref
Naoya Fujino, Hiroshi Kubo & Rose A Maciewicz. (2017) Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype. Laboratory Investigation 97:9, pages 1047-1062.
Crossref
Crossref
Jane Antony & Ruby Yun-Ju Huang. (2017) AXL-Driven EMT State as a Targetable Conduit in Cancer. Cancer Research 77:14, pages 3725-3732.
Crossref
Crossref
David Volk & Ganesh Lokesh. (2017) Development of Phosphorothioate DNA and DNA Thioaptamers. Biomedicines 5:3, pages 41.
Crossref
Crossref
Canan Kasikara, Sushil Kumar, Stanley Kimani, Wen-I Tsou, Ke Geng, Viralkumar Davra, Ganapathy Sriram, Connor Devoe, Khanh-Quynh N. Nguyen, Anita Antes, Allen Krantz, Grzegorz Rymarczyk, Andrzej Wilczynski, Cyril Empig, Bruce Freimark, Michael Gray, Kyle Schlunegger, Jeff Hutchins, Sergei V. Kotenko & Raymond B. Birge. (2017) Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression. Molecular Cancer Research 15:6, pages 753-764.
Crossref
Crossref
Wilhem Leconet, Myriam Chentouf, Stanislas du Manoir, Clément Chevalier, Audrey Sirvent, Imade Aït-Arsa, Muriel Busson, Marta Jarlier, Nina Radosevic-Robin, Charles Theillet, Dany Chalbos, Jean-Max Pasquet, André Pèlegrin, Christel Larbouret & Bruno Robert. (2017) Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clinical Cancer Research 23:11, pages 2806-2816.
Crossref
Crossref
Yinzhong Lu, Jun Wan, Zhifeng Yang, Xiling Lei, Qi Niu, Lanxin Jiang, Willemijn M. Passtoors, Aiping Zang, Patrick C. Fraering & Fang Wu. (2016) Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells. The FASEB Journal 31:4, pages 1382-1397.
Crossref
Crossref
Marie Schoumacher & Mike Burbridge. (2017) Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Current Oncology Reports 19:3.
Crossref
Crossref
Gaoyuan Jin, Zhenzhen Wang, Jianguang Wang, Like Zhang, Yanbin Chen, Pengfei Yuan & Dechun Liu. (2017) Expression of Axl and its prognostic significance in human breast cancer. Oncology Letters 13:2, pages 621-628.
Crossref
Crossref
Carl M Gay, Kavitha Balaji & Lauren Averett Byers. (2017) Giving AXL the axe: targeting AXL in human malignancy. British Journal of Cancer 116:4, pages 415-423.
Crossref
Crossref
Walter Keung, Amogh Boloor, Jason Brown, Andre Kiryanov, Anthony Gangloff, J. David Lawson, Robert Skene, Isaac Hoffman, Josephine Atienza, Jason Kahana, Ron De Jong, Pamela Farrell, Deepika Balakrishna & Petro Halkowycz. (2017) Structure-based optimization of 1 H -imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate. Bioorganic & Medicinal Chemistry Letters 27:4, pages 1099-1104.
Crossref
Crossref
Kavitha Balaji, Smruthi Vijayaraghavan, Lixia Diao, Pan Tong, Youhong Fan, Jason P.W. Carey, Tuyen N. Bui, Steve Warner, John V. Heymach, Kelly K. Hunt, Jing Wang, Lauren Averett Byers & Khandan Keyomarsi. (2017) AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research 15:1, pages 45-58.
Crossref
Crossref
Wanqin Wang, Jun Zhao, Xiaoxia Wen, Curtis Chun-Jen Lin, Junjie Li, Qian Huang, Yongqiang Yu, Shiaw-Yih Lin & Chun Li. (2017) MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media & Molecular Imaging 2017, pages 1-11.
Crossref
Crossref
Giridhar Mudduluru. 2017. Mechanisms of Molecular Carcinogenesis – Volume 1. Mechanisms of Molecular Carcinogenesis – Volume 1
39
60
.
Rolf A. Brekken & Katarzyna Wnuk-Lipinska. 2017. Biomarkers of the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment
221
239
.
Kjersti T. Davidsen, Gry S. Haaland, Maria K. Lie, James B. Lorens & Agnete S. T. Engelsen. 2017. Biomarkers of the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment
351
376
.
Anne von Mässenhausen, Johannes Brägelmann, Hannah Billig, Britta Thewes, Angela Queisser, Wenzel Vogel, Glen Kristiansen, Andreas Schröck, Friedrich Bootz, Peter Brossart, Jutta Kirfel & Sven Perner. (2016) Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. International Journal of Molecular Sciences 18:1, pages 7.
Crossref
Crossref
Erinn Rankin & Amato Giaccia. (2016) The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers 8:11, pages 103.
Crossref
Crossref
Chih-Ming Su, Ting-Yu Chang, Hui-Ping Hsu, Hui-Huang Lai, Jie-Ning Li, Yu-Jhen Lyu, Kuang-Tai Kuo, Ming-Te Huang, Jen-Liang Su & Pai-Sheng Chen. (2016) A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget 7:39, pages 63924-63936.
Crossref
Crossref
Gordon Moody, Brian Belmontes, Stephanie Masterman, Wei Wang, Chadwick King, Chris Murawsky, Trace Tsuruda, Shuying Liu, Robert Radinsky & Pedro J. Beltran. (2016)
Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors
in vivo
. International Journal of Cancer 139:6, pages 1340-1349.
Crossref
Crossref
Emily S. Humphrey, Shih-Ping Su, Adnan M. Nagrial, Falko Hochgräfe, Marina Pajic, Gillian M. Lehrbach, Robert G. Parton, Alpha S. Yap, Lisa G. Horvath, David K. Chang, Andrew V. Biankin, Jianmin Wu & Roger J. Daly. (2016) Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular & Cellular Proteomics 15:8, pages 2671-2685.
Crossref
Crossref
Li Tan, Zhang Zhang, Donglin Gao, Jinfeng Luo, Zheng-Chao Tu, Zhengqiu Li, Lijie Peng, Xiaomei Ren & Ke Ding. (2016) 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors. Journal of Medicinal Chemistry 59:14, pages 6807-6825.
Crossref
Crossref
Matthew Brown, James R M Black, Rohini Sharma, Justin Stebbing & David J Pinato. (2016)
Gene of the month:
Axl
. Journal of Clinical Pathology 69:5, pages 391-397.
Crossref
Crossref
Seiya Hattori, Eiji Kikuchi, Takeo Kosaka, Yasumasa Miyazaki, Nobuyuki Tanaka, Akira Miyajima, Shuji Mikami & Mototsugu Oya. (2015) Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma. Annals of Surgical Oncology 23:2, pages 663-670.
Crossref
Crossref
Margherita Iaboni, Valentina Russo, Raffaela Fontanella, Giuseppina Roscigno, Danilo Fiore, Elvira Donnarumma, Carla Lucia Esposito, Cristina Quintavalle, Paloma H Giangrande, Vittorio de Franciscis & Gerolama Condorelli. (2016) Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Molecular Therapy - Nucleic Acids 5, pages e289.
Crossref
Crossref
Ian Dransfield & Sarah Farnworth. 2016. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy
113
132
.
Janna V. Serbo, Scot Kuo, Shawna Lewis, Matthew Lehmann, Jiuru Li, David H. Gracias & Lewis H. Romer. (2015) Patterning of Fibroblast and Matrix Anisotropy within 3D Confinement is Driven by the Cytoskeleton. Advanced Healthcare Materials 5:1, pages 146-158.
Crossref
Crossref
Caitlin D. May, Jeannine Garnett, XiaoYan Ma, Sharon M. Landers, Davis R. Ingram, Elizabeth G. Demicco, Ghadah A. Al Sannaa, Tona Vu, Lixia Han, Yi Zhang, Christine M. Kivlin, Svetlana Bolshakov, Azad Abul Kalam, Juehui Liu, Fuguo Zhou, Dominique Broccoli, Wei-Lien Wang, Alexander J. Lazar, Raphael E. Pollock, Dina Lev & Keila E. Torres. (2015) AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer 15:1.
Crossref
Crossref
Zhenzhou Wu, Fan Bai, Liyun Fan, Wenshuai Pang, Ruiyu Han, Juan Wang, Yueping Liu, Xia Yan, Huijun Duan & Lingxiao Xing. (2015) Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas. Human Pathology 46:12, pages 1935-1944.
Crossref
Crossref
Anand Balupuri, Pavithra K. Balasubramanian & Seung Joo Cho. (2015) Molecular modeling study on Mer kinase inhibitors using 3D-QSAR and docking approaches. Medicinal Chemistry Research 24:10, pages 3730-3742.
Crossref
Crossref
Erika Martinelli, Giulia Martini, Claudia Cardone, Teresa Troiani, Giuseppina Liguori, Donata Vitagliano, Stefania Napolitano, Floriana Morgillo, Barbara Rinaldi, Rosa Marina Melillo, Federica Liotti, Anna Nappi, Roberto Bianco, Liberato Berrino, Loreta Pia Ciuffreda, Davide Ciardiello, Vincenzo Iaffaioli, Gerardo Botti, Fiorella Ferraiolo & Fortunato Ciardiello. (2015) AXL is an oncotarget in human colorectal cancer. Oncotarget 6:27, pages 23281-23296.
Crossref
Crossref
Romain Baer, Célia Cintas, Nicole Therville & Julie Guillermet-Guibert. (2015) Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?. Advances in Biological Regulation 59, pages 19-35.
Crossref
Crossref
Romain Gioia, Claire Trégoat, Pierre-Yves Dumas, Valérie Lagarde, Valérie Prouzet-Mauléon, Vanessa Desplat, Audrey Sirvent, Vincent Praloran, Eric Lippert, Arnaud Villacreces, Wilhem Leconet, Bruno Robert, Isabelle Vigon, Serge Roche, François-Xavier Mahon & Jean-Max Pasquet. (2015) CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia. The Journal of Pathology 237:1, pages 14-24.
Crossref
Crossref
Piergiorgio Pettazzoni, Andrea Viale, Parantu Shah, Alessandro Carugo, Haoqiang Ying, Huamin Wang, Giannicola Genovese, Sahil Seth, Rosalba Minelli, Tessa Green, Emmet Huang-Hobbs, Denise Corti, Nora Sanchez, Luigi Nezi, Matteo Marchesini, Avnish Kapoor, Wantong Yao, Maria E. Di Francesco, Alessia Petrocchi, Angela K. Deem, Kenneth Scott, Simona Colla, Gordon B. Mills, Jason B. Fleming, Timothy P. Heffernan, Philip Jones, Carlo Toniatti, Ronald A. DePinho & Giulio F. Draetta. (2015) Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research 75:6, pages 1091-1101.
Crossref
Crossref
Juliano D. Paccez, Kristal Duncan, Akhona Vava, Ricardo G. Correa, Towia A. Libermann, M. Iqbal Parker & Luiz F. Zerbini. (2015) Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Molecular Biology of the Cell 26:5, pages 821-831.
Crossref
Crossref
Zhuang Yu, Xianchao Li, Cuizhu Ge, Hongzong Si, Lianhua Cui, Hua Gao, Yunbo Duan & Honglin Zhai. (2014) 3D-QSAR modeling and molecular docking study on Mer kinase inhibitors of pyridine-substituted pyrimidines. Molecular Diversity 19:1, pages 135-147.
Crossref
Crossref
Simona Gurzu. (2015) Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World Journal of Clinical Cases 3:5, pages 393.
Crossref
Crossref
Jennifer W. Harris, Tianyan Gao & B. Mark Evers. 2015. Intestinal Tumorigenesis. Intestinal Tumorigenesis
101
135
.
Greg Lemke. 2015. Receptor Tyrosine Kinases: Family and Subfamilies. Receptor Tyrosine Kinases: Family and Subfamilies
53
77
.
Konrad Steinestel, Stefan Eder, Andres Jan Schrader & Julie Steinestel. (2014) Clinical significance of epithelial‐mesenchymal transition. Clinical and Translational Medicine 3:1.
Crossref
Crossref
W Leconet, C Larbouret, T Chardès, G Thomas, M Neiveyans, M Busson, M Jarlier, N Radosevic-Robin, M Pugnière, F Bernex, F Penault-Llorca, J-M Pasquet, A Pèlegrin & B Robert. (2013) Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 33:47, pages 5405-5414.
Crossref
Crossref
Rosimeire Coura Barcelos, Karin Juliane Pelizzaro-Rocha, Julio Cezar Pastre, Marina Pereira Dias, Carmen Veríssima Ferreira-Halder & Ronaldo Aloise Pilli. (2014) A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness. European Journal of Medicinal Chemistry 87, pages 745-758.
Crossref
Crossref
Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang & Balazs Halmos. (2014) AXL kinase as a novel target for cancer therapy. Oncotarget 5:20, pages 9546-9563.
Crossref
Crossref
Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi & Jeff Settleman. (2014) AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs. Cancer Research 74:20, pages 5878-5890.
Crossref
Crossref
Clémence Feneyrolles, Aurélia Spenlinhauer, Léa Guiet, Bénédicte Fauvel, Bénédicte Daydé-Cazals, Pierre Warnault, Gwénaël Chevé & Aziz Yasri. (2014) Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors. Molecular Cancer Therapeutics 13:9, pages 2141-2148.
Crossref
Crossref
Felicity M. Davis, Teneale A. Stewart, Erik W. Thompson & Gregory R. Monteith. (2014) Targeting EMT in cancer: opportunities for pharmacological intervention. Trends in Pharmacological Sciences 35:9, pages 479-488.
Crossref
Crossref
Rhonda L. Bitting, Daneen Schaeffer, Jason A. Somarelli, Mariano A. Garcia-Blanco & Andrew J. Armstrong. (2014) The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer and Metastasis Reviews 33:2-3, pages 441-468.
Crossref
Crossref
Kuo-Chou Chiu, Chien-Hsing Lee, Shyun-Yeu Liu, Chi-Tai Yeh, Ren-Yeong Huang, Da-Yo Yuh, Jen-Chan Cheng, Yu-Ting Chou & Yi-Shing Shieh. (2014) Protumoral effect of macrophage through Axl activation on mucoepidermoid carcinoma. Journal of Oral Pathology & Medicine 43:7, pages 538-544.
Crossref
Crossref
Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman & Yusuke Shiozawa. (2014) Molecular Pathways: Niches in Metastatic Dormancy. Clinical Cancer Research 20:13, pages 3384-3389.
Crossref
Crossref
Robert Torka, Kinga P?nzes, Simone Gusenbauer, Christine Baumann, Istv?n Szabadkai, L?szl? ?rfi, Gy?rgy K?ri & Axel Ullrich. (2014) Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy. Neoplasia 16:4, pages 301-318.
Crossref
Crossref
M K Asiedu, F D Beauchamp-Perez, J N Ingle, M D Behrens, D C Radisky & K L Knutson. (2013) AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33:10, pages 1316-1324.
Crossref
Crossref
Juliano D. Paccez, Matjaz Vogelsang, M. Iqbal Parker & Luiz F. Zerbini. (2013) The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. International Journal of Cancer 134:5, pages 1024-1033.
Crossref
Crossref
Sridhar Nimmagadda, Mrudula Pullambhatla, Ala Lisok, Chaoxin Hu, Anirban Maitra & Martin G Pomper. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochemical and Biophysical Research Communications 443:2, pages 635-640.
Crossref
Crossref
Ashley N. Rettew, Patrick J. Getty & Edward M. Greenfield. 2014. Current Advances in Osteosarcoma. Current Advances in Osteosarcoma
47
66
.
Jhy-Shrian Huang, Chun-Yu Cho, Chih-Chen Hong, Ming-De Yan, Mao-Chih Hsieh, Jong-Ding Lay, Gi-Ming Lai, Ann-Lii Cheng & Shuang-En Chuang. (2013) Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. Free Radical Biology and Medicine 65, pages 1246-1256.
Crossref
Crossref
Hiba el Sayadi, Daniel Pissaloux, Laurent Alberti, Severine Tabone-Eglinger, Dominique Ranchere, Anne Val?rie Decouvelaere, Eric Tabone, Isabelle Ray-Coquard, Christophe Caux, J?rome Fayette & Jean-Yves Blay. (2013) Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Targeted Oncology 8:4, pages 261-269.
Crossref
Crossref
Keith M. Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, Priscilla M. Zhang, Andrew D. Redfern, Lisa M. Stuart, Gregory J. Goodall & Peter J. Leedman. (2013) Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Molecular Cancer Therapeutics 12:11, pages 2541-2558.
Crossref
Crossref
Aaron S. MeyerMiles A. MillerFrank B. GertlerDouglas A. Lauffenburger. (2013) The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells. Science Signaling 6:287.
Crossref
Crossref
Russell S. Taichman, Lalit R. Patel, Rachel Bedenis, Jingcheng Wang, Savannah Weidner, Taibriana Schumann, Kenji Yumoto, Janice E. Berry, Yusuke Shiozawa & Kenneth J. Pienta. (2013) GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation. PLoS ONE 8:4, pages e61873.
Crossref
Crossref
J D Paccez, G J Vasques, R G Correa, J F Vasconcellos, K Duncan, X Gu, M Bhasin, T A Libermann & L F Zerbini. (2012) The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32:6, pages 689-698.
Crossref
Crossref
Y. Zhang, Y-J. Tang, Y. Man, F. Pan, Z-H. Li & L-S. Jia. (2013) Knockdown of AXL Receptor Tyrosine Kinase in Osteosarcoma Cells Leads to Decreased Proliferation and Increased Apoptosis. International Journal of Immunopathology and Pharmacology 26:1, pages 179-188.
Crossref
Crossref
Dana S. Neel & Trever G. Bivona. (2013) Secrets of Drug Resistance in NSCLC Exposed by New Molecular Definition of EMT. Clinical Cancer Research 19:1, pages 3-5.
Crossref
Crossref
Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K. Tumula, Monique B. Nilsson, Jayanthi Gudikote, Hai Tran, Robert J.G. Cardnell, David J. Bearss, Steven L. Warner, Jason M. Foulks, Steven B. Kanner, Varsha Gandhi, Nancy Krett, Steven T. Rosen, Edward S. Kim, Roy S. Herbst, George R. Blumenschein, J. Jack Lee, Scott M. Lippman, K. Kian Ang, Gordon B. Mills, Waun K. Hong, John N. Weinstein, Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna & John V. Heymach. (2013) An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research 19:1, pages 279-290.
Crossref
Crossref
Laura Cerchia, Carla L Esposito, Simona Camorani, Anna Rienzo, Loredana Stasio, Luigi Insabato, Andrea Affuso & Vittorio de Franciscis. (2012) Targeting Axl With an High-affinity Inhibitory Aptamer. Molecular Therapy 20:12, pages 2291-2303.
Crossref
Crossref
C. Li, Y. Ren, X. Jia, P. Liang, W. Lou, L. He, M. Li, S. Sun & H. Wang. (2012) Twist overexpression promoted epithelial-to-mesenchymal transition of human peritoneal mesothelial cells under high glucose. Nephrology Dialysis Transplantation 27:11, pages 4119-4124.
Crossref
Crossref
A E J Rogers, J P Le, S Sather, B M Pernu, D K Graham, A M Pierce & A K Keating. (2011) Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 31:38, pages 4171-4181.
Crossref
Crossref
Chien-Hsing Lee, Ching-Yu Yen, Shyun-Yeu Liu, Chi-Kang Chen, Chi-Fu Chiang, Shine-Gwo Shiah, Pei-Hsuan Chen & Yi-Shing Shieh. (2011) Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma. Annals of Surgical Oncology 19:S3, pages 500-508.
Crossref
Crossref
Gunther Boysen, Damaris Bausch-Fluck, Claudio R. Thoma, Anna M. Nowicka, Daniel P. Stiehl, Igor Cima, Van-Duc Luu, Adriana von Teichman, Thomas Hermanns, Tullio Sulser, Barbara Ingold-Heppner, Niklaus Fankhauser, Roland H. Wenger, Wilhelm Krek, Peter Krek, Bernd Wollscheid & Holger Moch. (2012) Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma. Neoplasia 14:6, pages 535-IN17.
Crossref
Crossref
Anjali Mishra, Jingcheng Wang, Yusuke Shiozawa, Samantha McGee, Jinkoo Kim, Younghun Jung, Jeena Joseph, Janice E. Berry, Aaron Havens, Kenneth J. Pienta & Russell S. Taichman. (2012) Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer. Molecular Cancer Research 10:6, pages 703-712.
Crossref
Crossref
Niki A. Ottenhof, Folkert H. M. Morsink, Fiebo ten Kate, Cornelis J. F. van Noorden & G. Johan A. Offerhaus. (2012) Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cellular Oncology 35:2, pages 119-126.
Crossref
Crossref
Alexis Mollard, Steven L. Warner, Lee T. Call, Mark L. Wade, Jared J. Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati & David J. Bearss. (2011) Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors. ACS Medicinal Chemistry Letters 2:12, pages 907-912.
Crossref
Crossref
Anjali Mishra, Yusuke Shiozawa, Kenneth J. Pienta & Russell S. Taichman. (2011) Homing of Cancer Cells to the Bone. Cancer Microenvironment 4:3, pages 221-235.
Crossref
Crossref
Mark Mackiewicz, Konrad Huppi, Jason J. Pitt, Tiffany H. Dorsey, Stefan Ambs & Natasha J. Caplen. (2011) Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Research and Treatment 130:2, pages 663-679.
Crossref
Crossref
Anupam Verma, Steven L. Warner, Hariprasad Vankayalapati, David J. Bearss & Sunil Sharma. (2011) Targeting Axl and Mer Kinases in Cancer. Molecular Cancer Therapeutics 10:10, pages 1763-1773.
Crossref
Crossref
Kathryn Tworkoski, Garima Singhal, Sebastian Szpakowski, Christina Ivins Zito, Antonella Bacchiocchi, Viswanathan Muthusamy, Marcus Bosenberg, Michael Krauthammer, Ruth Halaban & David F. Stern. (2011) Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma. Molecular Cancer Research 9:6, pages 801-812.
Crossref
Crossref
Hector Alvarez, Joanna Opalinska, Li Zhou, Davendra Sohal, Melissa J. Fazzari, Yiting Yu, Christina Montagna, Elizabeth A. Montgomery, Marcia Canto, Kerry B. Dunbar, Jean Wang, Juan Carlos Roa, Yongkai Mo, Tushar Bhagat, K. H. Ramesh, Linda Cannizzaro, J. Mollenhauer, Reid F. Thompson, Masako Suzuki, Stephen Meltzer, Ari Melnick, John M. Greally, Anirban Maitra & Amit Verma. (2011) Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis. PLoS Genetics 7:3, pages e1001356.
Crossref
Crossref
K Vuoriluoto, H Haugen, S Kiviluoto, J-P Mpindi, J Nevo, C Gjerdrum, C Tiron, J B Lorens & J Ivaska. (2010) Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30:12, pages 1436-1448.
Crossref
Crossref
Kejun Zhang, Dong Chen, Xuelong Jiao, Shaoyan Zhang, Xiangping Liu, Jingyu Cao, Liqun Wu & Dongsheng Wang. (2011) Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Laboratory Investigation 91:3, pages 426-438.
Crossref
Crossref
Xianzhou Song, Hua Wang, Craig D. Logsdon, Asif Rashid, Jason B. Fleming, James L. Abbruzzese, Henry F. Gomez, Douglas B. Evans & Huamin Wang. (2011) Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117:4, pages 734-743.
Crossref
Crossref
Harald J. Maier, Thomas Wirth & Hartmut Beug. (2010) Epithelial-Mesenchymal Transition in Pancreatic Carcinoma. Cancers 2:4, pages 2058-2083.
Crossref
Crossref
Erinn B. Rankin, Katherine C. Fuh, Tiffany E. Taylor, Adam J. Krieg, Margaret Musser, Jenny Yuan, Kevin Wei, Calvin J. Kuo, Teri A. Longacre & Amato J. Giaccia. (2010) AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer. Cancer Research 70:19, pages 7570-7579.
Crossref
Crossref
X Ye, Y Li, S Stawicki, S Couto, J Eastham-Anderson, D Kallop, R Weimer, Y Wu & L Pei. (2010) An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29:38, pages 5254-5264.
Crossref
Crossref
Sacha J. Holland, Alison Pan, Christian Franci, Yuanming Hu, Betty Chang, Weiqun Li, Matt Duan, Allan Torneros, Jiaxin Yu, Thilo J. Heckrodt, Jing Zhang, Pingyu Ding, Ayodele Apatira, Joanne Chua, Ralf Brandt, Polly Pine, Dane Goff, Rajinder Singh, Donald G. Payan & Yasumichi Hitoshi. (2010) R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer. Cancer Research 70:4, pages 1544-1554.
Crossref
Crossref
Christine Gjerdrum, Crina Tiron, Torill Høiby, Ingunn Stefansson, Hallvard Haugen, Tone Sandal, Karin Collett, Shan Li, Emmet McCormack, Bjørn Tore Gjertsen, David R. Micklem, Lars A. Akslen, Carlotta Glackin & James B. Lorens. (2009) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences 107:3, pages 1124-1129.
Crossref
Crossref